益生菌结合间歇性蓝光治疗对高胆红素血症新生儿经皮胆红素、免疫球蛋白的影响

摘要/Abstract

摘要： 目的探讨益生菌结合间歇性蓝光治疗对高胆红素血症新生儿经皮胆红素、免疫球蛋白的影响。方法回顾性分析2022年10月至2023年10月绵阳市妇幼保健院收治的123例高胆红素血症新生儿资料,根据治疗方法不同分为对照组和联合组。对照组(54例)给予间歇性蓝光治疗,联合组(69例)加用双歧杆菌三联活菌治疗。对比2组高胆红素血症新生儿临床疗效、经皮胆红素水平、T淋巴细胞亚群(CD3⁺、CD4⁺、CD4⁺/CD8⁺)、免疫球蛋白(IgM、IgG)水平及并发症总发生率。结果联合组治疗总有效率为98.55%(68/69),高于对照组的90.74%(49/54)(P<0.05);联合组治疗后经皮胆红素水平为(93.57±24.09)μmol/L,显著低于对照组的[(135.21±21.63)μmol/L,P<0.05]。联合组治疗后CD4⁺、CD4⁺/CD8⁺水平分别为(49.61±6.78)%、(2.05±0.54),显著高于对照组的[(28.97±8.21)%、(0.98±0.32),P<0.05]。联合组治疗后IgM水平为(0.71±0.16)g/L,显著高于对照组的[(0.47±0.12)g/L,P<0.05]。联合组并发症总发生率为1.45%(1/69),低于对照组的12.96%(7/54)(χ²=4.846,P=0.028)。结论益生菌结合间歇性蓝光治疗可以改善高胆红素血症新生儿的经皮胆红素水平和机体免疫功能,且安全性好。

关键词: 益生菌, 间歇性蓝光治疗, 高胆红素血症, 经皮胆红素, 免疫球蛋白

Abstract: Objective To explore the effects of probiotics combined with intermittent blue light therapy on percutaneous bilirubin and immunoglobulin levels in neonates with hyperbilirubinemia. Methods A retrospective analysis was conducted on the clinical data of 123 newborns with hyperbilirubinemia admitted to Mianyang Maternal and Child Health Hospital from October 2022 to October 2023. According to different treatment methods, patients were divided into a control group(n=54) and a combination group(n=69). The control group received intermittent blue light therapy, while the combination group received probiotic bifidobacteria triple active powder combined with intermittent blue light therapy. The clinical efficacy, percutaneous bilirubin levels, T lymphocyte subsets, immunoglobulin (IgM, IgG) levels and total complication rate of hyperbilirubinemia neonates in two groups were compared. Results The effective rate in combination group (98.55%) was higher compared with control group (90.74%) (P<0.05). The transcutaneous bilirubin level in the combination group after treatment was (93.57±24.09)μmol/L, significantly lower than that in the control group (135.21±21.63) μmol/L, P<0.05]. The CD4⁺ levels and CD4⁺/CD8⁺ ratio in the combination group after treatment were (49.61±6.78)% and (2.05±0.54), respectively, which were significantly higher than those in the control group [(28.97±8.21)% and (0.98±0.32), respectively, P<0.05]. The IgM level in the combination group after treatment was (0.71±0.16) g/L, significantly higher than that in the control group (0.47±0.12) g/L, P<0.05]. The total complication rate in combined group was 1.45% (1/69), which was lower compared with control group (12.96%) (7/54) (χ²=4.846, P=0.028). Conclusion Probiotics combined with intermittent blue light therapy can improve the transcutaneous bilirubin levels and immune function of newborns with hyperbilirubinemia, with favorable safety.

Key words: Probiotics, Intermittent blue light therapy, Hyperbilirubinemia, Percutaneous bilirubin, Immunoglobulin

任晓桃, 李怡, 郑婕, 翟盟. 益生菌结合间歇性蓝光治疗对高胆红素血症新生儿经皮胆红素、免疫球蛋白的影响[J]. 肝脏, 2025, 30(8): 1138-1141.

REN Xiao-tao, LI Yi, ZHENG Jie, ZHAI Meng. Effect of probiotics combined with intermittent blue light therapy on percutaneous bilirubin and immunoglobulin in neonates with hyperbilirubinemia[J]. Chinese Hepatolgy, 2025, 30(8): 1138-1141.

/ 推荐

参考文献

[1] Lee B, Piersante T, Calkins K L. Neonatal hyperbilirubinemia[J]. Pediatr Ann, 2022 ,51(6): e219-e227.
[2] 杨柳. 新生儿日间光疗模式在新生儿高胆红素血症治疗中的应用效果[J]. 保健医学研究与实践, 2022, 19(10):66-69.
[3] 叶珍珍, 沈伊娜. 酪酸梭菌二联活菌联合苯巴比妥结合蓝光治疗早期新生儿高胆红素血症疗效评估[J]. 安徽医药, 2020, 24(9):1821-1824.
[4] Par E J, Hughes C A, DeRico P. Neonatal hyperbilirubinemia: evaluation and treatment[J]. Am Fam Physician, 2023, 107(5):525-534.
[5] 唐炜, 卢红艳, 孙勤, 等. 布拉氏酵母菌联合光疗治疗新生儿高胆红素血症的疗效:前瞻性随机对照研究[J]. 中国当代儿科杂志, 2020, 22(11):1149-1153.
[6] 陈维静, 常佩. 双歧杆菌三联活菌散联合间歇蓝光照射治疗新生儿高胆红素血症的临床效果[J]. 临床医学研究与实践, 2023, 8(10):63-65.
[7] Deshmukh J, Deshmukh M, Patole S. Probiotics for the management of neonatal hyperbilirubinemia: a systematic review of randomized controlled trials[J]. J Matern Fetal Neonatal Med, 2019, 32(1):154-163.
[8] 陈华, 谢影, 白彦红, 等. 普米克令舒联合氨溴索雾化与丙种球蛋白治疗新生儿肺炎的效果[J]. 分子诊断与治疗杂志, 2023, 15(4):568-572.
[9] 蔡岳鞠, 黎小兰, 王萍, 等. 执行2014《新生儿高胆红素血症诊断和治疗专家共识》后单中心新生儿高胆红素血症诊疗现状[J]. 中华新生儿科杂志(中英文),2024, 39(5):278-282.
[10] 赖志飞, 钟华文, 房子胜. 益生菌(酪酸梭菌肠球菌三联活菌片)辅助治疗新生儿黄疸的临床疗效观察[J]. 海峡药学, 2020, 32(7):170-171.
[11] Qattea I, Farghaly M A A, Elgendy M, et al. Neonatal hyperbilirubinemia and bilirubin neurotoxicity in hospitalized neonates: analysis of the US database[J]. Pediatr Res, 2022, 91(7): 1662-1668.
[12] Sampurna M T A, Pratama D C, Visuddho V, et al. A review of existing neonatal hyperbilirubinemia guidelines in Indonesia[J]. F1000Res,2023,11(1):1534.
[13] Bhutani V K, Wong R J, Turkewitz D, et al. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation: technical report[J]. Pediatrics,2024,154(3):e2024068026.
[14] Chastain A P, Geary A L, Bogenschutz K M. Managing neonatal hyperbilirubinemia: an updated guideline[J]. JAAPA,2024,37(10):19-25.
[15] Ebbesen F, Vandborg P K, Donneborg M L. The effectiveness of phototherapy using blue-green light for neonatal hyperbilirubinemia-danish clinical trials[J]. Semin Perinatol,2021, 45(1):151358.
[16] Sarathy L, Chou J H, Romano-Clarke G, et al. Bilirubin measurement and phototherapy use after the AAP 2022 newborn hyperbilirubinemia guideline[J]. Pediatrics,2024,153(4):e2023 063323.
[17] Gottimukkala S B, Lobo L, Gautham K S, et al. Intermittent phototherapy versus continuous phototherapy for neonatal jaundice[J]. Cochrane Database Syst Rev,2023,3(3):CD008168.
[18] Demirel H N, Ozumut S S, Ovalι H F. Continuous versus intermittent phototherapy in treatment of neonatal jaundice: a randomized controlled trial[J]. Eur J Pediatr,2024,183(8): 3389-3396.
[19] Qian X, Zhao Y. Assessment of the therapeutic effect of probiotics combined with intermittent blue light irradiation on pathological jaundice in neonates[J]. Minerva Pediatr (Torino), 2024,76(1):133-135.
[20] Fang J, Yang Y, Xie W. Chinese expert consensus on the application of live combined bifidobacterium, lactobacillus, and enterococcus powder/capsule in digestive system diseases (2021)[J]. J Gastroenterol Hepatol, 2023,38(7):1089-1098.
[21] 赵扬扬, 杨晓林, 陈欢欢, 等. 双歧杆菌三联活菌散治疗小儿急性感染性腹泻的临床效果[J]. 保健医学研究与实践,2021,18(6):78-81.
[22] 秦晓莉, 任晨虹. 茵栀黄口服液与双歧杆菌三联活菌散联用对新生儿黄疸的影响[J]. 实用临床医药杂志,2020,24(10):126-128,132.
[23] 陈桦. 双歧杆菌三联活菌散联合间歇冷光源蓝光治疗新生儿高胆红素血症的效果[J]. 妇儿健康导刊,2024,3(23):65-68.
[24] Nasief H, Alaifan M A, Tamur S, et al. Effectiveness of phototherapy with and without probiotics for the treatment of indirect hyperbilirubinaemia in preterm neonates: a randomised controlled trial[J]. Paediatr Int Child Health,2024,44(1):24-29.
[25] 张红伟. 双歧杆菌三联活菌肠溶胶囊联合蓝光照射治疗新生儿病理性黄疸的效果[J]. 中国民康医学,2023,35(01):51-53.
[26] Eghbalian F, Sabzehei M K, Talesh S T, et al. The effect of probiotics on phototherapy for bilirubin reduction in term neonates: a randomized controlled trial[J]. Curr Pediatr Rev, 2024,21(1):85-90.
[27] Raturi M, Adhikari B, Kalra A, et al. Reporting an immune-mediated neonatal hyperbilirubinemia following Rh (D) isoimmunization in an Indian term newborn bearing A B Rh (D) positive phenotype[J]. Indian J Pathol Microbiol,2023,66(3):669-671.
[28] 王向平, 陈占芳. 持续及间歇蓝光照射治疗新生儿高胆红素血症疗效观察[J]. 中国药物与临床,2021,21(11):1932-1934.
[29] 张建梅, 刘发盛, 陈欣, 等. 新生儿高胆红素血症诊治中T淋巴细胞和白介素-6变化的研究[J]. 中华临床医师杂志(电子版),2018,12(10):571-575.
[30] 吴新婷, 卞伟妮, 郑玲芳, 等. 口服益生菌联合茵栀黄口服液治疗新生儿高胆红素血症的效果及免疫机制分析[J]. 中国医药,2022,17(07):1029-1033.
[31] 林柏杏, 杨英桂, 朱华民. 高胆红素血症对新生仔鼠sPD-L1表达水平及T淋巴细胞免疫功能的影响[J]. 重庆医学,2023,52(11):1601-1605+1610.